treprostinil SC
Selected indexed studies
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. (N Engl J Med, 2021) [PMID:33440084]
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. (Eur Respir J, 2023) [PMID:37080567]
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. (N Engl J Med, 2026) [PMID:41812190]
_Worker-drafted node — pending editorial review._
Connections
treprostinil SC is a side effect of
Sources
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (2010) pubmed
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. (2021) pubmed
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. (2023) pubmed
- Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results. (2024) pubmed
- Treprostinil sodium Pharmacia. (2002) pubmed
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. (2026) pubmed
- Inhaled treprostinil: a therapeutic review. (2012) pubmed
- Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. (2022) pubmed
- Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities. (2025) pubmed
- Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future. (2025) pubmed